Interleukin 6 Receptor (IL6R) Antibody
780€ (1 ml)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Interleukin 6 Receptor (IL6R) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx173186
tested applications
WB, IHC, IF/ICC
Description
This product is currently in development. The lead time for this product may be several months. Please contact us at
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Interleukin 6 Receptor (IL6R) |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Please enquire. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | IL6Q,gp80,CD126,HIES5,IL-6R,IL6RA,IL6RQ,IL-1Ra,IL-6RA,IL6QTL,IL-6R-1,L-6R-Alpha,IL-6Rα |
| Background | Antibody anti-IL6R |
| Status | RUO |
Descripción
IL6R is a key component of the interleukin-6 (IL6) signaling pathway, consisting of a membrane-bound and soluble form (sIL6R), which binds IL6 and mediates downstream effects via the gp130 co-receptor This interaction activates the JAK/STAT3, MAPK, and PI3K/AKT pathways, regulating immune responses, inflammation, and hematopoiesis IL6R signaling is critical in acute-phase responses, B cell maturation, and T cell proliferation Dysregulation of IL6R activity is implicated in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus (SLE) In cancer, IL6R signaling supports tumor progression, angiogenesis, and immune evasion Therapeutic targeting of IL6R, such as with tocilizumab, is effective in reducing inflammation and cytokine storm in conditions like COVID-19, autoimmune disorders, and hematological malignancies
Related Products
Human IL-6Rα(Interleukin-6 receptor subunit alpha) ELISA Kit
Ver Producto
Monkey IL-6R ELISA Kit
Ver Producto